Search

Your search keyword '"Hugosson, Jonas"' showing total 1,060 results
Start Over Author "Hugosson, Jonas"
1,060 results on '"Hugosson, Jonas"'

252. Prostate cancer: ESMO Consensus Conference Guidelines 2012

Author

Horwich, A., primary, Hugosson, J., additional, de Reijke, T., additional, Wiegel, T., additional, Fizazi, K., additional, Kataja, V., additional, Parker, Chris, additional, Bellmunt, Joaquim, additional, Berthold, Dominik, additional, Bill-Axelson, Anna, additional, Carlsson, Sigrid, additional, Daugaard, Gedske, additional, De Meerleer, Gert, additional, de Reijke, Theo, additional, Dearnaley, David, additional, Fizazi, Karim, additional, Fonteyne, Valérie, additional, Gillessen, Silke, additional, Heinrich, Daniel, additional, Horwich, Alan, additional, Hugosson, Jonas, additional, Kataja, Vesa, additional, Kwiatkowski, Maciej, additional, Nilsson, Sten, additional, Padhani, Anwar, additional, Papandreou, Christos, additional, Roobol, Monique, additional, Sella, Avishay, additional, Valdagni, Riccardo, additional, Van der Kwast, Theo, additional, Verhagen, Paul, additional, and Wiegel, Thomas, additional

Published
2013
Full Text
View/download PDF

255. Excess all-cause mortality in the evaluation of a screening trial to account for selective participation

Author

Kranse, Ries, primary, van Leeuwen, Pim J, additional, Hakulinen, Timo, additional, Hugosson, Jonas, additional, Tammela, Teuvo L, additional, Ciatto, Stefano, additional, Roobol, Monique J, additional, Zappa, Marco, additional, Aus, Gunar, additional, Bangma, Chris H, additional, Moss, Sue M, additional, Auvinen, Anssi, additional, and Schröder, Fritz H, additional

Published
2013
Full Text
View/download PDF

262. Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005

Author

Adolfsson, Jan, Garmo, Hans, Varenhorst, Eberhard, Ahlgren, Göran, Ahlstrand, Christer, Andrén, Ove, Bill-Axelson, Anna, Bratt, Ola, Damber, Jan-Erik, Hellström, Karin, Hellström, Magnus, Holmberg, Erik, Holmberg, Lars, Hugosson, Jonas, Johansson, Jan-Erik, Petterson, Bill, Törnblom, Magnus, Widmark, Anders, Stattin, Pär, Adolfsson, Jan, Garmo, Hans, Varenhorst, Eberhard, Ahlgren, Göran, Ahlstrand, Christer, Andrén, Ove, Bill-Axelson, Anna, Bratt, Ola, Damber, Jan-Erik, Hellström, Karin, Hellström, Magnus, Holmberg, Erik, Holmberg, Lars, Hugosson, Jonas, Johansson, Jan-Erik, Petterson, Bill, Törnblom, Magnus, Widmark, Anders, and Stattin, Pär

Abstract

OBJECTIVE: The incidence of prostate cancer is rising rapidly in Sweden and there is a need to better understand the pattern of diagnosis, tumor characteristics and treatment. MATERIAL AND METHODS: Between 1996 and 2005, all new cases of adenocarcinoma of the prostate gland were intended to be registered in the National Prostate Cancer Register (NPCR). This register contains information on diagnosing unit, date of diagnosis, cause of diagnosis, tumor grade, tumor stage according to the TNM classification in force, serum prostate-specific antigen (PSA) levels at diagnosis and primary treatment given within the first 6 months after diagnosis. RESULTS: In total, 72,028 patients were registered, comprising >97% of all pertinent incident cases of prostate cancer in the Swedish Cancer Register (SCR). During the study period there was a considerable decrease in median age at the time of diagnosis, a stage migration towards smaller tumors, a decrease in median serum PSA values at diagnosis, a decrease in the age-standardized incidence rate of men diagnosed with distant metastases or with a PSA level of > 100 ng/ml at diagnosis and an increase in the proportion of tumors with Gleason score <6. Relatively large geographical differences in the median age at diagnosis and the age-standardized incidence of cases with category T1c tumors were observed. Treatment with curative intent increased dramatically and treatment patterns varied according to geographical region. In men with localized tumors and a PSA level of <20 ng/ml at diagnosis, expectant treatment was more commonly used in those aged > or =75 years than in those aged <75 years. Also, the pattern of endocrine treatment varied in different parts of Sweden. CONCLUSIONS: All changes in the register seen over time are consistent with increased diagnostic activity, especially PSA testing, resulting in an increased number of cases with early disease, predominantly tumors in category T1c. The patterns of diag

Published
2007
Full Text
View/download PDF

263. The Effect of Start and Stop Age at Screening on the Risk of Being Diagnosed with Prostate Cancer.

Author

Godtman, Rebecka Arnsrud, Carlsson, Sigrid, Holmberg, Erik, Stranne, Johan, and Hugosson, Jonas

Subjects
PROSTATE cancer risk factors, DIAGNOSIS, PROSTATE cancer, PROSTATE biopsy, MEDICAL screening, ANTIGENS
Abstract

Purpose We investigated the effect of age and number of screens on the risk of prostate cancer diagnosis. Materials and Methods Since 1995 the Göteborg randomized population based prostate cancer screening trial has invited men biennially for prostate specific antigen testing, until the upper age limit of 70 years. Men with a prostate specific antigen above the threshold of 2.5 ng/ml were recommended further evaluation including 10-core biopsy (sextant before 2009). The present study comprises 9,065 men born between 1930 and 1943 (1944 excluded due to different screening algorithm). Complete attendees were defined as men who accepted all screening invitations (maximum 3 to 9 invitations). The cumulative incidence of prostate cancer was calculated using standard methods. Results Of the 3,488 (38%) complete attendees 667 were diagnosed with prostate cancer (followup 1995 to June 30, 2014). At age 70 years there was no significant difference in prostate cancer risk among those who started screening at the age of 52 (9 screens), 55 (7 screens) or 60 (5 screens) years. However, the cumulative risk of prostate cancer diagnosis increased dramatically with age, and was 7.9% at age 60, 15% at age 65 and 21% at age 70 for men who had been screened 4 or more times. Conclusions There was no clear association between risk of prostate cancer and the number of screens. Starting screening at an early age appears to advance the time of prostate cancer diagnosis but does not seem to increase the risk of being diagnosed with the disease. Age at termination of screening is strongly associated with the risk of being diagnosed with prostate cancer. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

264. Rule-based versus probabilistic selection for active surveillance using three definitions of insignificant prostate cancer.

Author

Venderbos, Lionne, Roobol, Monique, Bangma, Chris, Bergh, Roderick, Bokhorst, Leonard, Nieboer, Daan, Godtman, Rebecka, Hugosson, Jonas, Kwast, Theodorus, and Steyerberg, Ewout

Subjects
PROSTATE cancer treatment, HISTOPATHOLOGY, COMPARATIVE studies, MEDICAL screening, PERFORMANCE evaluation
Abstract

Purpose: To study whether probabilistic selection by the use of a nomogram could improve patient selection for active surveillance (AS) compared to the various sets of rule-based AS inclusion criteria currently used. Methods: We studied Dutch and Swedish patients participating in the European Randomized study of Screening for Prostate Cancer (ERSPC). We explored which men who were initially diagnosed with cT1-2, Gleason 6 (Gleason pattern ≤3 + 3) had histopathological indolent PCa at RP [defined as pT2, Gleason pattern ≤3 and tumour volume (TV) ≤0.5 or TV ≤ 1.3 ml, and TV no part of criteria (NoTV)]. Rule-based selection was according to the Prostate cancer Research International: Active Surveillance (PRIAS), Klotz, and Johns Hopkins criteria. An existing nomogram to define probability-based selection for AS was refitted for the TV1.3 and NoTV indolent PCa definitions. Results: 619 of 864 men undergoing RP had cT1-2, Gleason 6 disease at diagnosis and were analysed. Median follow-up was 8.9 years. 229 (37 %), 356 (58 %), and 410 (66 %) fulfilled the TV0.5, TV1.3, and NoTV indolent PCa criteria at RP. Discriminating between indolent and significant disease according to area under the curve (AUC) was: TV0.5: 0.658 (PRIAS), 0.523 (Klotz), 0.642 (Hopkins), 0.685 (nomogram). TV1.3: 0.630 (PRIAS), 0.550 (Klotz), 0.615 (Hopkins), 0.646 (nomogram). NoTV: 0.603 (PRIAS), 0.530 (Klotz), 0.589 (Hopkins), 0.608 (nomogram). Conclusions: The performance of a nomogram, the Johns Hopkins, and PRIAS rule-based criteria are comparable. Because the nomogram allows individual trade-offs, it could be a good alternative to rigid rule-based criteria. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

265. Geographical variation in incidence of prostate cancer in Sweden.

Author

Stattin, Pär, Johansson, Robert, Lodnert, Ronald, Andrén, Ove, Bill-Axelson, Anna, Bratt, Ola, Damber, Jan-Erik, Hellström, Magnus, Hugosson, Jonas, Lundgren, Rolf, Törnblom, Magnus, Varenhorst, Eberhard, Johansson, Jan-Erik, Stattin, Pär, Johansson, Robert, Lodnert, Ronald, Andrén, Ove, Bill-Axelson, Anna, Bratt, Ola, Damber, Jan-Erik, Hellström, Magnus, Hugosson, Jonas, Lundgren, Rolf, Törnblom, Magnus, Varenhorst, Eberhard, and Johansson, Jan-Erik

Abstract

OBJECTIVE: To investigate the geographical variation in prostate cancer incidence in Sweden, in particular the incidences of screening-detected tumours and curative treatment of prostate cancer. MATERIAL AND METHODS: Data were retrieved from the National Prostate Cancer Register of Sweden for all cases of prostate cancer diagnosed in the year 2000-01. There were a total of 14 376 cases of prostate cancer and the mean total annual age-adjusted incidence was 197/100 000 men. There were 3318 cases in tumour category T1c, i.e. non-palpable tumours diagnosed during work-up for an elevated serum level of prostate-specific antigen, 1006 of which (30%) were asymptomatic and detected at a health check-up. RESULTS: The difference between the counties with the lowest and highest age-adjusted incidences per 100 000 men of total prostate cancer was almost twofold (128 vs 217). The corresponding variation in incidence of category T1c tumours was more than fourfold (13 vs 60); the difference in incidence of T1c tumours detected in asymptomatic men was up to 10-fold (2 vs 20); and there was more than a fourfold variation in incidence of curative treatment between counties (13 vs 67). Measured incidences were mostly highest in urban regions and in counties with university hospitals. CONCLUSION: There are large geographical variations in prostate cancer incidence and in the frequency of curative treatment for prostate cancer in Sweden and there appear to be large geographical variations in the uptake of prostate cancer screening.

Published
2005
Full Text
View/download PDF

266. Inguinal hernia in stage M0 prostate cancer: a comparison of incidence in men treated with and without radical retropubic prostatectomy--an analysis of 1105 patients

Author

Stranne, Johan, Hugosson, Jonas, Iversen, Peter, Morris, Thomas, Lodding, Pär, Stranne, Johan, Hugosson, Jonas, Iversen, Peter, Morris, Thomas, and Lodding, Pär

Abstract

To analyze the incidence of inguinal hernia (IH) in a large group of patients with nonmetastatic prostate cancer who were treated nonoperatively, and to compare it with the incidence in a subset of patients who had undergone radical retropubic prostatectomy (RRP). IH has been reported in 12% to 21% of men at a mean period of 6 to 10 months after RRP. However, whether IH truly represents a complication after RRP has been somewhat debatable owing to the lack of proper control groups.

Published
2005

270. Quality-of-Life Effects of Prostate-Specific Antigen Screening

Author

Heijnsdijk, Eveline A.M., primary, Wever, Elisabeth M., additional, Auvinen, Anssi, additional, Hugosson, Jonas, additional, Ciatto, Stefano, additional, Nelen, Vera, additional, Kwiatkowski, Maciej, additional, Villers, Arnauld, additional, Páez, Alvaro, additional, Moss, Sue M., additional, Zappa, Marco, additional, Tammela, Teuvo L.J., additional, Mäkinen, Tuukka, additional, Carlsson, Sigrid, additional, Korfage, Ida J., additional, Essink-Bot, Marie-Louise, additional, Otto, Suzie J., additional, Draisma, Gerrit, additional, Bangma, Chris H., additional, Roobol, Monique J., additional, Schröder, Fritz H., additional, and de Koning, Harry J., additional

Published
2012
Full Text
View/download PDF

274. Evaluating the Prostate Cancer Prevention Trial High Grade prostate cancer risk calculator in 10 international biopsy cohorts: results from the prostate biopsy collaborative group

Author

Ankerst, Donna P., primary, Boeck, Andreas, additional, Freedland, Stephen J., additional, Stephen Jones, J., additional, Cronin, Angel M., additional, Roobol, Monique J., additional, Hugosson, Jonas, additional, Kattan, Michael W., additional, Klein, Eric A., additional, Hamdy, Freddie, additional, Neal, David, additional, Donovan, Jenny, additional, Parekh, Dipen J., additional, Klocker, Helmut, additional, Horninger, Wolfgang, additional, Benchikh, Amine, additional, Salama, Gilles, additional, Villers, Arnauld, additional, Moreira, Daniel M., additional, Schröder, Fritz H., additional, Lilja, Hans, additional, Vickers, Andrew J., additional, and Thompson, Ian M., additional

Published
2012
Full Text
View/download PDF

277. Prostate-Cancer Mortality at 11 Years of Follow-up

Author

Schröder, Fritz H., primary, Hugosson, Jonas, additional, Roobol, Monique J., additional, Tammela, Teuvo L.J., additional, Ciatto, Stefano, additional, Nelen, Vera, additional, Kwiatkowski, Maciej, additional, Lujan, Marcos, additional, Lilja, Hans, additional, Zappa, Marco, additional, Denis, Louis J., additional, Recker, Franz, additional, Páez, Alvaro, additional, Määttänen, Liisa, additional, Bangma, Chris H., additional, Aus, Gunnar, additional, Carlsson, Sigrid, additional, Villers, Arnauld, additional, Rebillard, Xavier, additional, van der Kwast, Theodorus, additional, Kujala, Paula M., additional, Blijenberg, Bert G., additional, Stenman, Ulf-Hakan, additional, Huber, Andreas, additional, Taari, Kimmo, additional, Hakama, Matti, additional, Moss, Sue M., additional, de Koning, Harry J., additional, and Auvinen, Anssi, additional

Published
2012
Full Text
View/download PDF

279. Towards an Optimal Interval for Prostate Cancer Screening

Author

van Leeuwen, Pim J., primary, Roobol, Monique J., additional, Kranse, Ries, additional, Zappa, Marco, additional, Carlsson, Sigrid, additional, Bul, Meelan, additional, Zhu, Xiaoye, additional, Bangma, Chris H., additional, Schröder, Fritz H., additional, and Hugosson, Jonas, additional

Published
2012
Full Text
View/download PDF

280. Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group

Author

Ankerst, Donna P., primary, Boeck, Andreas, additional, Freedland, Stephen J., additional, Thompson, Ian M., additional, Cronin, Angel M., additional, Roobol, Monique J., additional, Hugosson, Jonas, additional, Stephen Jones, J., additional, Kattan, Michael W., additional, Klein, Eric A., additional, Hamdy, Freddie, additional, Neal, David, additional, Donovan, Jenny, additional, Parekh, Dipen J., additional, Klocker, Helmut, additional, Horninger, Wolfgang, additional, Benchikh, Amine, additional, Salama, Gilles, additional, Villers, Arnauld, additional, Moreira, Daniel M., additional, Schröder, Fritz H., additional, Lilja, Hans, additional, and Vickers, Andrew J., additional

Published
2011
Full Text
View/download PDF

281. Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group

Author

Roobol, Monique J., primary, Schröder, F. H., additional, Hugosson, Jonas, additional, Jones, J. Stephen, additional, Kattan, Michael W., additional, Klein, Eric A., additional, Hamdy, Freddie, additional, Neal, David, additional, Donovan, Jenny, additional, Parekh, Dipen J., additional, Ankerst, Donna, additional, Bartsch, George, additional, Klocker, Helmut, additional, Horninger, Wolfgang, additional, Benchikh, Amine, additional, Salama, Gilles, additional, Villers, Arnauld, additional, Freedland, Stephen J., additional, Moreira, Daniel M., additional, Vickers, Andrew J., additional, Lilja, Hans, additional, and Steyerberg, Ewout W., additional

Published
2011
Full Text
View/download PDF

288. LAPPRO: A prospective multicentre comparative study of robot-assisted laparoscopic and retropubic radical prostatectomy for prostate cancer

Author

Thorsteinsdottir, Thordis, primary, Stranne, Johan, additional, Carlsson, Stefan, additional, Anderberg, Bo, additional, Björholt, Ingela, additional, Damber, Jan-Erik, additional, Hugosson, Jonas, additional, Wilderäng, Ulrica, additional, Wiklund, Peter, additional, Steineck, Gunnar, additional, and Haglind, Eva, additional

Published
2010
Full Text
View/download PDF

293. The Relationship between Prostate-Specific Antigen and Prostate Cancer Risk: The Prostate Biopsy Collaborative Group

Author

Vickers, Andrew J., primary, Cronin, Angel M., additional, Roobol, Monique J., additional, Hugosson, Jonas, additional, Jones, J. Stephen, additional, Kattan, Michael W., additional, Klein, Eric, additional, Hamdy, Freddie, additional, Neal, David, additional, Donovan, Jenny, additional, Parekh, Dipen J., additional, Ankerst, Donna, additional, Bartsch, George, additional, Klocker, Helmut, additional, Horninger, Wolfgang, additional, Benchikh, Amine, additional, Salama, Gilles, additional, Villers, Arnauld, additional, Freedland, Steve J., additional, Moreira, Daniel M., additional, Schröder, Fritz H., additional, and Lilja, Hans, additional

Published
2010
Full Text
View/download PDF

296. Is delayed radical prostatectomy in men with low‐risk screen‐detected prostate cancer associated with a higher risk of unfavorable outcomes?

Author

van den Bergh, Roderick C. N., primary, Steyerberg, Ewout W., additional, Khatami, Ali, additional, Aus, Gunnar, additional, Pihl, Carl Gustaf, additional, Wolters, Tineke, additional, van Leeuwen, Pim J., additional, Roobol, Monique J., additional, Schröder, Fritz H., additional, and Hugosson, Jonas, additional

Published
2010
Full Text
View/download PDF

297. Inherited genetic variant predisposes to aggressive but not indolent prostate cancer

Author

Xu, Jianfeng, primary, Zheng, Siqun Lilly, additional, Isaacs, Sarah D., additional, Wiley, Kathleen E., additional, Wiklund, Fredrik, additional, Sun, Jielin, additional, Kader, A. Karim, additional, Li, Ge, additional, Purcell, Lina D., additional, Kim, Seong-Tae, additional, Hsu, Fang-Chi, additional, Stattin, Pär, additional, Hugosson, Jonas, additional, Adolfsson, Jan, additional, Walsh, Patrick C., additional, Trent, Jeffrey M., additional, Duggan, David, additional, Carpten, John, additional, Grönberg, Henrik, additional, and Isaacs, William B., additional

Published
2010
Full Text
View/download PDF

298. The effect of study arm on prostate cancer treatment in the large screening trial ERSPC

Author

Wolters, Tineke, primary, Roobol, Monique J., additional, Steyerberg, Ewout W., additional, van den Bergh, Roderick C.N., additional, Bangma, Chris H., additional, Hugosson, Jonas, additional, Ciatto, Stefano, additional, Kwiatkowski, Maciej, additional, Villers, Arnauld, additional, Luján, Marcos, additional, Nelen, Vera, additional, Tammela, Teuvo L.J., additional, and Schröder, Fritz H., additional

Published
2010
Full Text
View/download PDF

300. Prostate-Specific Antigen Velocity for Early Detection of Prostate Cancer: Result from a Large, Representative, Population-based Cohort

Author

Vickers, Andrew J., primary, Wolters, Tineke, additional, Savage, Caroline J., additional, Cronin, Angel M., additional, O’Brien, M. Frank, additional, Pettersson, Kim, additional, Roobol, Monique J., additional, Aus, Gunnar, additional, Scardino, Peter T., additional, Hugosson, Jonas, additional, Schröder, Fritz H., additional, and Lilja, Hans, additional

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results